Search

everythinglearnresearchcommunity

for

Search:↓

A user's progress in treating their hair loss with Finasteride, Minoxidil and Dermarolling; they discussed details of their routine and others congratulated them on their success.

RepliCel has purchased Trichoscience, and they have a video about hair multiplication. The conversation also mentions treatments like Minoxidil, finasteride, and RU58841.

Hair loss discussion includes treatments Minoxidil, Finasteride, and RU58841. Verteporfin considered for treating donor areas after hair transplants.

Verteporfin may improve hair transplant outcomes and reduce scarring, potentially allowing patients to avoid finasteride. Dr. Barghouthi seeks collaborations, volunteers, and financial support for research on verteporfin.org.

The conversation is about someone experiencing slow but steady hair regrowth using topical Minoxidil and 1mg Finasteride daily since mid-December. Another person commented positively on the progress.

The user experienced thicker hair after 4.5 months using oral finasteride, oral and topical minoxidil, biotin, magnesium, zinc, vitamin D, iodine, and head massages. They also noticed improved muscle gains at the gym, possibly linked to finasteride.

Research and science related to a minor improvement in hair growth caused by the use of verteporfin, as well as potential treatments such as Minoxidil, Finasteride, and RU58841.

The conversation discusses using verteporfin for hair regrowth and minimizing scarring after hair transplants. Some individuals plan to self-administer verteporfin, potentially in combination with microneedling, as an alternative to hair transplants.

A 32-year-old is happy with hair regrowth after 4 months using oral finasteride and topical minoxidil, with noticeable improvement in the last month. Others suggest continued use could lead to full coverage.

Verteporfin is being explored for hair regeneration, with unofficial trials and updates shared online. Efforts are being made to encourage more surgeons to trial verteporfin for donor hair regeneration.

Winlevi (clascoterone 1%) is being discussed as a potential hair loss treatment. Users are considering its use despite concerns about its delivery method.

The conversation is about incorporating tretinoin into a hair loss regimen after using minoxidil and finasteride for years, with discussions on the effectiveness of minoxidil and the potential benefits of adding tretinoin. Users also discuss the effectiveness of oral minoxidil and other topical treatments like diclofenac and fluocinolone.

The user experienced a sudden and severe hair loss after 1.5 years of successful treatment with finasteride and minoxidil. They plan to check their thyroid and vitamin D levels as potential causes.

The conversation discusses GT20029, a compound by Kintor Pharma that degrades androgen receptors and is in trials, with potential as a hair loss cure. Another promising treatment mentioned is an antibody that blocks prolactin and has shown positive results in macaques.

The conversation discusses the potential of a new hair loss treatment, GT20029, which may prevent hair loss by destroying androgen receptors on the scalp. Users express hope for the treatment's success and speculate on its usage routine, effectiveness, and possible side effects.

A user is seeking advice on treating a chin scar with Verteporfin, noting that higher doses were more effective. Another user responds that they do not use it, without providing further explanation.

The post and conversation are about a user's 4-month hair regrowth progress using 3mg minoxidil, 2.5mg biotin, 1.1mg finasteride daily, and occasional dermarolling. The user reports significant improvement without using topical treatments.

Amplifica is testing a compound called AMP-303 for hair loss, but it's not Scube3 or osteopontin. The timing for the results from the clinical trial is unknown.

Doctors are testing verteporfin topically for healing and potential regeneration after transplants. The user is asking how it is formulated for topical use, such as if it's mixed with a carrier gel.

The conversation discusses positive initial trial results for GT20029, a topical compound for hair loss that degrades androgen receptors, potentially requiring only weekly application. Participants express hope for this treatment to be more effective and convenient than current options like Minoxidil, Finasteride, and RU58841.

The user has been using a topical solution of minoxidil 5% and finasteride 0.025% daily, along with dermastamping every two weeks and ketoconazole shampoo twice a week for four months. The treatment is for hair loss.

The conversation is about creating a higher concentration of the newly FDA-approved hair loss treatment, Clascoterone (Winlevi), through compounding pharmacies and possibly organizing group purchases. Some users are unfamiliar with Winlevi and are asking for an explanation of the drug.

The conversation discusses the potential use of verteporfin for hair loss treatment, with one user mentioning their surgeon's interest in trying it and another noting its research status and clinical use as a YAP inhibitor. Some users debate the market size, availability of generics, and the optimism in the hair loss community regarding new treatments.

A progress report on hair growth after four months of using 0.5mg finasteride taken every other day, topical 5% minoxidil twice a day and some dermarolling for treatment of hair loss.

The conversation is about sourcing Winlevi (clascoterone) for personal use in the EU. The user is specifically looking for a non-generic version.

HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.

The conversation discusses GT20029, a new topical drug for hair loss and acne without notable side effects, which has been accepted for investigational use in China. Some users express skepticism about the legitimacy of the company and the potential for other drugs like RU58841 to be developed due to patent expiration and lack of profitability.

Veradermics is a promising new treatment for hair loss, essentially a repackaged version of Minoxidil. The user is optimistic about its potential effectiveness.

PP405 is moving to late-stage trials, showing potential for hair regrowth, with 31% of male patients experiencing a 20% increase in hair density. Veradermics is developing an oral minoxidil version, and there is interest in combining treatments for better results.

Hair loss improvement in 4 months using finasteride and minoxidil. Users express surprise and interest in trying minoxidil.